Clinical trials: Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
Hypertension, Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
Neck-to-Waist Ratio Identifies Chronic Hypertensive Phenotype and Occlusive Myocardial Infarction in Patients Presenting With Acute Coronary Syndrome
aim of this study was to evaluate the relationship between multiple conventional and novel anthropometric measurements and hypertension in patients presenting to the ED with ACS and whether anthropometric indices differ according…
- Conditions
- Hypertension, Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), Obesity (Disorder)
- Trial name
- NCT07676656
- Where
- Turkey (Türkiye)
- Volunteers
- 238 people
- Sponsor
- Ercis Sehit Rıdvan Cevik State Hospital
Coronary Artery Disease, Acute Coronary Syndrome
Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI
Cangrelor is an intravenous P2Y12 inhibitor utilized as a bridge to achieve adequate platelet inhibition until oral P2Y12 inhibitors achieve their full antiplatelet effects in patients undergoing coronary stenting.
- Trial name
- SWAP-6 (NCT04668144)
- Testing
- Cangrelor, Prasugrel
- Where
- United States
- Volunteers
- 359 people
- Sponsor
- University of Florida
Patients With Acute Coronary Syndrome
Prasugrel Versus Clopidogrel in Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
Background: Both prasugrel and clopidogrel are prescribed drugs which compete as platelet inhibitors in patients with acute coronary syndrome (ACS).
- Trial name
- NCT01090336
- Where
- Germany
- Volunteers
- 26 people
- Sponsor
- Heidelberg University
Acute Coronary Syndromes
Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI
The primary objective of this clinical trial is to evaluate safety of switching from fondaparinux to either unfractionated heparin or bivalirudin for patients experiencing acute coronary syndrome undergoing percutaneous coronary…
- Trial name
- SWITCHIII (NCT00464087)
- Testing
- Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin
- Where
- 7 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Medstar Health Research Institute
Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia
Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI
Investigators aimed to evaluate efficacy and safety of early Initiation of evolocumab and combination lipid-lowering agent (statin + Ezetimibe) on lipid profiles changes in patients with ACS undergoing PCI
- Trial name
- C-STAR (NCT05661552)
- Testing
- Evolocumab 140 MG/ML, Rosuvastatin 5mg, Ezetimibe 10mg
- Where
- South Korea
- Volunteers
- 108 people
- Sponsor
- Yonsei University
Acute Coronary Syndromes
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors With Statin for ACS Patients
Cardiovascular diseases (CVDs) remain the leading cause of death globally, with a dominant contribution from atherosclerotic CVD (ASCVD).
- Trial name
- NCT07736313
- Testing
- PCSK9 inhibitor plus rosuvastatin 20 mg tab, Rosuvastatin 20 Mg Oral Tablet
- Volunteers
- 120 people
- Sponsor
- Assiut University
Non ST Segment Elevation Acute Coronary Syndrome
Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI
It is designed to test the hypothesis that high loading dose(360mg) ticagrelor versus conventional loading dose(180mg) will result in a higher inhibition of platelet aggregation(IPA) without increasing the bleeding events.
- Trial name
- NCT01962428
- Testing
- ticagrelor
- Where
- 2 sites in China
- Volunteers
- 250 people
- Sponsor
- General Hospital of Chinese Armed Police Forces
Acute Coronary Syndrome
Intensive Lipid Lowering Treatment in Non-ST-elevation Acute Coronary Syndrome (NSTE-ACS) Patients
PCI has been one of the most common choice of treatments for patients with coronary artery disease, and studies indicated that intensive statin treatment before PCI could reduce adverse events as comparing to the placebo.
- Trial name
- ILLEPE-ACS (NCT01040936)
- Testing
- Atorvastatin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
IVUS-Guided Sirolimus-Coated Balloon Versus Sirolimus-Eluting Stent for De Novo Large Vessel Lesions in ACS
The goal of this interventional study is to evaluate the efficacy and safety of an intravascular ultrasound (IVUS)-guided sirolimus-coated balloon (SCB)-based strategy versus planned sirolimus-eluting stent (SES) implantation in…
- Trial name
- IVUS-SCB (NCT07796412)
- Testing
- IVUS-Guided Sirolimus-Coated Balloon, IVUS-Guided Sirolimus-Eluting Stent
- Where
- China
- Volunteers
- 150 people
- Sponsor
- China National Center for Cardiovascular Diseases
Myocardial Infarction (MI), ST-Elevation Myocardial Infarction
Drug-Coated Balloon Primary PCI in ST-Segment Elevation Myocardial Infarction
Drug-eluting stent (DES)-based primary percutaneous intervention (pPCI) has been established as the standard of care for patients presenting with ST-segment elevation myocardial infarction (STEMI), having demonstrated superiority…
- Conditions
- Myocardial Infarction (MI), ST-Elevation Myocardial Infarction, STEMI, STEMI (STE-ACS)
- Trial name
- DCB-STEMI (NCT07436429)
- Testing
- Drug-Coated Balloon
- Where
- Austria
- Volunteers
- 300 people
- Sponsor
- Medical University of Vienna
Acute Coronary Syndrome
DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid
Among patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI) and stent implantation, 17.5% are both at high bleeding risk (HBR) and have undergone complex PCI, which also places them at…
- Trial name
- BETA-DAPT (NCT07391358)
- Testing
- Patient decision aid to support shared decision-making between patients and clinicians
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- Montreal Heart Institute